JAKARTA - The New York-based Synchron company announced on Thursday February 1, that it has acquired equity stocks in medical component maker Acquandas, in a bid to improve their brain implant manufacturing surgery.
Synchron, which is more advanced in the development of brain implants than Elon Musk's Neuralink, did not disclose the magnitude of the shares they acquired or the financial details of the deal.
SEE ALSO:
-
| TEKNOLOGI
Kebijakan Baru App Store Dianggap Merugikan, Epic Games Adukan Apple ke Pengadilan
01 Februari 2024, 17:30 -
| TEKNOLOGI
Bermitra dengan Microsoft, Apple Vision Pro Bisa Digunakan untuk Bekerja
01 Februari 2024, 17:05 -
| TEKNOLOGI
Fitur Circle to Search Sekarang Tersedia di Pixel 8, Pixel 8 Pro dan Samsung Galaxy S24
01 Februari 2024, 16:30
The company launched a second trial of their brain implantation devices in the US early last year, by registering patients suffering from severe paralysis due to amyotrophic lateral sclerosis (ALS), stroke, spinal injury, or multiple sclerosis.
Like Neuralink, Synchron aims to help patients with severe paralysis control digital devices. They received human testing approval from the US FDA in July 2021, five years after submitting an application.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
